Development of thioredoxin reductase inhibitors towards new anticancer agents

EranetRus_2017

Acronym THIOREDIN
Call ERA.Net RUS Plus Call 2017 “HEALTH”
Project coordinator Dr. chem. Raivis Žalubovskis,
Latvian Institute of Organic Synthesis, Latvia
Project partners University of Belgrade, Serbia
Saint Petersburg State University, Russia
Implementation period 2018 – 2019
 Costs for Latvian partner 139 370 EUR

The main objective of the project is to develop novel anticancer agents targeting thioredoxin reductase (TrxR) and investigate their effects in cancer cell lines, including those with multidrug resistant phenotypes.

To achieve this objective multidisciplinary research is planned where efforts in organic synthesis, in vitro enzyme inhibition screening and cytotoxicity studies on cancer and normal cell lines will be combined.

The project includes two scientific activities:

1) Design and synthesis of TrxR inhibitors,

2) In vitro investigation of obtained compounds (inhibition of TrxR, cytotoxicity studies on cancer and normal cell lines).

The main expected result of the project is knowledge on relationships of inhibition of TrxR and cytotoxicity on cancer cells including multidrug resistant phenotypes. This in turn will facilitate development of novel anticancer drug in future.